DDrare: Database of Drug Development for Rare Diseases

226. 間質性膀胱炎（ハンナ型）
［臨床試験数：133，薬物数：151（DrugBank：46），標的遺伝子数：48，標的パスウェイ数：137］

Searched query = "Interstitial cystitis with Hunners ulcer", "Interstitial cystitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 2% sodium chondroitin sulfate; 5% lidocaine/5 mg/ml 0.02% estradiol compound cream; AGN 203818; AQX-1125; AQX-1125 100 mg; AQX-1125 200 mg; ASP3652; ASP6294; Adalimumab; Alkalinized Lidocaine-Heparin; Amitriptyline; BOTOX 200U in normal saline; Bladder Instillations; Bladder instillation WITH triamcinolone acetonide; Bladder instillation WITHOUT triamcinolone acetonide; Bladder instillation with heparin/ lidocaine; Botox; Botulinum toxin A; Buckwheat; Bupivacaine; CICLOSPORIN; Cannabidiol; Cannabidiol vaginal suppository; Capsaicin; Certolizumab pegol; Chondroitin sulfate; Ciclosporin; Ciklosporin; Combination Product: Hyperbaric Oxygen Therapy-; Cyclosporine; DMSO; DMSO cocktail; Device: Intermittent Exposure to Oxygen via Oro-Nasal Mask; Device: interferential current; Dexmedetomidine; Dimethyl sulfoxide; ERB-041; Estradiol; Fospropofol; Fospropofol (Lusedra®) 10; Fospropofol (Lusedra®) 12; Fospropofol (Lusedra®) 6.5; Fremanezumab; Gefapixant; Glycine; Gralise; Heparin; Heparin & Alkalinized Lidocaine Bladder Instillation; Hyaluronic Acid and Chondroitin Sulfate; Hyaluronic acid; Hyaluronic acid/chondroitin sulfate; Hydrogen; IC Cocktail; IPD® (Japanese tradename); IPD® (suplatast tosilate); Intravesical onabotulinumtoxinA injection; JNJ-42160443; KRP-116D; Ketorolac; Ketorolac Tromethamine; LP-08 20mg; LP-08 80mg; LiRIS 400 mg; LiRIS low dose and LiRIS high dose; LiRIS®; LiRIS® 400 mg; Lidocaine; Lidocaine Releasing Intravesical System - LiRIS®; Liposome encapsulated BoNT-A; Liposomes; Low-dose naltrexone; MMF; MN-001; MN-001 BID; MR-MC-01; Metoprolol; Metoprolol Tartrate Oral Tablet; Mirabegron; Mycofenolate Mofetil (MMF); Mycophenolate; Mycophenolate Mofetil; Mycophenolate mofetil; NALOXONE HYDROCHLORIDE; Naloxone; Naltrexone; Normal Saline; Normal saline; Normal saline instillation; Nortriptyline; OXN 10/5 mg PR; OXN 20/10 mg PR; OXN 5/2.5 mg PR; OXYCODONE HYDROCHLORIDE; Omalizumab; Onabotulinum Toxin A; Onabotulinumtoxin A; OnabotulinumtoxinA; Other: Hyperbaric Oxygen Therapy; Other: Normal Saline; Other: Saline as a nasal spray; Other: inactive drug; Other: normal saline; Oxycodone; Oxycodone naloxone prolonged release tablets; Oxycodone/naloxone prolonged release t; Oxycodone/naloxone prolonged release tablets 10/5 mg; Oxycodone/naloxone prolonged release tablets 20/10 mg; Oxycodone/naloxone prolonged release tablets 5/2.5 mg; Oxygen; Oxytocin; PD 0299685; PD 0299685 at 15mg BID; PD 0299685 at 30mg BID; PD-0299685; PF-04383119; Pentosan polysulfate; Pentosan polysulfate sodium 100 mg; Placebo; Platelet enriched plasma; Platelet-Rich Plasma; Procedure: Pelvic Floor Physical Therapy; Procedure: Sham Cystoscopy Procedure; Procedure: Urodynamic study; Procedure: injections on posterior bladder wall excluding the trigone; Procedure: injections upper aspect of trigone of urinary bladder; Prograf; Propiverine; Propiverine Hydrochloride; RIMSO 50; RN624, RI624; Rimso 50; SANDIMMUN; SI-722; Sandimmun Neoral; Sildenafil; Sulfate; Suplatast tosilate; TACROLIMUS; TTI-1612; Tacrolimus; Tanezumab; Targinact 10 mg/5 mg prolonged-release tablets; Targinact 20mg/10 mg prolonged-release tablets; Targinact 5mg/2.5 mg prolonged-release tablets; Tramadol; Triamcinolone; Tromethamine; URG101; Water; YM672; YM672 (IPD®)

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2005-003367-23-DE (EUCTR)	13/02/2006	23/11/2005	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis - Not available	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis - Not available	Interstitial Cystitis / Painful Bladder Syndrome MedDRA version: 8.0;Level: LLT;Classification code 10008928	Product Name: YM672 (IPD®) Product Code: YM672 INN or Proposed INN: Suplatast tosilate Other descriptive name: IPD® (Japanese tradename)	Astellas Pharma Europe B.V.	NULL	Not Recruiting	Female: yes Male: yes	150	Phase 2	Germany;Sweden
2	EUCTR2005-003367-23-DK (EUCTR)	06/02/2006	21/12/2005	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis - Not available	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis - Not available	Interstitial Cystitis / Painful Bladder Syndrome MedDRA version: 8.0;Level: LLT;Classification code 10008928	Trade Name: IPD® (suplatast tosilate) Product Name: YM672 (IPD®) Product Code: YM672 INN or Proposed INN: Suplatast tosilate Other descriptive name: IPD® (Japanese tradename)	Astellas Pharma Europe B.V.	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	150	Phase 2	Denmark;Germany;Sweden
3	EUCTR2005-003367-23-SE (EUCTR)	01/02/2006	06/12/2005	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis - Not available	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis - Not available	Interstitial Cystitis / Painful Bladder Syndrome MedDRA version: 8.0;Level: LLT;Classification code 10008928	Trade Name: IPD® (suplatast tosilate) Product Name: YM672 (IPD®) Product Code: YM672 INN or Proposed INN: Suplatast tosilate Other descriptive name: IPD® (Japanese tradename)	Astellas Pharma Europe B.V.	NULL	Not Recruiting	Female: yes Male: yes	150	Phase 2	Germany;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2005-003367-23-DE
(EUCTR)

13/02/2006

23/11/2005

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis - Not available

Interstitial Cystitis / Painful Bladder Syndrome
MedDRA version: 8.0;Level: LLT;Classification code 10008928

Product Name: YM672 (IPD®)
Product Code: YM672
INN or Proposed INN: Suplatast tosilate
Other descriptive name: IPD® (Japanese tradename)

Astellas Pharma Europe B.V.

NULL

Not Recruiting

Female: yes
Male: yes

150

Phase 2

Germany;Sweden

EUCTR2005-003367-23-DK
(EUCTR)

06/02/2006

21/12/2005

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis - Not available

Interstitial Cystitis / Painful Bladder Syndrome
MedDRA version: 8.0;Level: LLT;Classification code 10008928

Trade Name: IPD® (suplatast tosilate)
Product Name: YM672 (IPD®)
Product Code: YM672
INN or Proposed INN: Suplatast tosilate
Other descriptive name: IPD® (Japanese tradename)

Astellas Pharma Europe B.V.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

150

Phase 2

Denmark;Germany;Sweden

EUCTR2005-003367-23-SE
(EUCTR)

01/02/2006

06/12/2005

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis - Not available

Interstitial Cystitis / Painful Bladder Syndrome
MedDRA version: 8.0;Level: LLT;Classification code 10008928

Trade Name: IPD® (suplatast tosilate)
Product Name: YM672 (IPD®)
Product Code: YM672
INN or Proposed INN: Suplatast tosilate
Other descriptive name: IPD® (Japanese tradename)

Astellas Pharma Europe B.V.

NULL

Not Recruiting

Female: yes
Male: yes

150

Phase 2

Germany;Sweden